Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DAVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAVEDave$256.33+2.8%$215.98$149.20▼$287.69$3.38B3.93598,017 shs478,176 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAVEDave0.00%-8.35%+39.74%+36.05%+131.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAVEDave$256.33+2.8%$215.98$149.20▼$287.69$3.38B3.93598,017 shs478,176 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAVEDave0.00%-8.35%+39.74%+36.05%+131.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAVEDave 2.86Moderate Buy$325.8827.13% UpsideCurrent Analyst Ratings BreakdownLatest DAVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026DAVEDave Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$332.005/6/2026DAVEDave Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$328.00 ➝ $342.005/6/2026DAVEDave CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026DAVEDave Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$335.00 ➝ $365.005/4/2026DAVEDave Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$290.005/4/2026DAVEDave Keefe, Bruyette & WoodsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$295.00 ➝ $330.004/24/2026DAVEDave Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/10/2026DAVEDave CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/10/2026DAVEDave Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$310.00 ➝ $335.003/13/2026DAVEDave UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAVEDave$554.20M6.27$13.23 per share19.37$15.03 per share17.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAVEDave$195.87M$15.5516.4815.77N/A37.22%77.70%45.59%N/ALatest DAVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026DAVEDave$2.86$3.64+$0.78$4.02$153.67 million$158.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDAVEDaveN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAVEDave0.953.863.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAVEDave18.01%Insider OwnershipCompanyInsider OwnershipDAVEDave28.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAVEDave25013.56 million9.70 millionOptionableDAVE HeadlinesRecent News About These CompaniesDave Chappelle on Finding Balance: Yellow Springs Saved My Life2 hours ago | allhiphop.comADave Coulier can’t eat solid food, lost 45 lbs. amid throat cancer battle2 hours ago | nydailynews.com‘Full House’ Dave Coulier Opens Up About Weight Loss During Cancer Treatment2 hours ago | yahoo.comDave Coulier says cancer treatment has affected his speech, appearance2 hours ago | msn.comDave Coulier Lost 45 Pounds After Cancer Treatment2 hours ago | msn.comDave Coulier addresses weight loss amid cancer battleMay 8 at 1:38 PM | aol.comABBC radio presenter Dave Llewellyn dies aged 57May 8 at 1:38 PM | msn.comDave Coulier reveals health update to fans, addresses his appearanceMay 8 at 1:38 PM | usatoday.comDave Coulier Shares Honest Health Update Amid Cancer Battle After Fans Express ConcernMay 8 at 8:37 AM | aol.comADave Coulier shares health update after 'extensive radiation' that changed his appearance and voiceMay 8 at 8:37 AM | msn.comDave Coulier shares health update while addressing fans' concerns about his appearance, reveals he lost 45 lbsMay 8 at 8:37 AM | msn.comDave Matthews Tribute Band opens Portland summer concert seriesMay 7 at 5:35 PM | aol.comADave Chappelle says awful trans jokes were just a misunderstanding: “People think it’s me versus the gay community”May 7 at 5:35 PM | msn.comDave Coulier shares health update after fans express concern over his appearance (video)May 7 at 5:35 PM | msn.comDave Grohl Details the Sign He Got to Keep Making Music After Death of Kurt Cobain: 'All I Wanted to Do Was Disappear'May 7 at 5:35 PM | msn.comDave Chappelle and Michelle Obama take jabs at Trump in ‘IMO’ interview: ‘Tried to tell the people’May 7 at 5:35 PM | thegrio.comTDave Coulier reveals weight loss: 'Haven't eaten solid food in months'May 7 at 5:35 PM | msn.comDoes DAVE INC (DAVE) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?May 7 at 10:55 AM | zacks.comStrs Ohio Raises Stake in Dave Inc. $DAVEMay 7 at 5:44 AM | marketbeat.comDave (NASDAQ:DAVE) Shares Gap Down - Here's WhyMay 6 at 5:13 PM | marketbeat.comDave (NASDAQ:DAVE) Stock Price Expected to Rise, Citizens Jmp Analyst SaysMay 6 at 10:47 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAVE Company DescriptionsDave NASDAQ:DAVE$256.33 +7.06 (+2.83%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$252.41 -3.92 (-1.53%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
